Find results that contain all of your keywords. Content filter is on. Search will return best illustrations, stock vectors and clipart.
Make it so!
You have chosen to exclude "" from your results.

Choose orientation:
Explore cartoons & images using related keywords:

pdb2kd3

sclerostin

wnt

bone

growth

regulator

sost

 osteocyte gene signaling pathway calcitonin sclerosteosis van buchem disease romosozumab osteoporosis structure peptide protein amino acid molecule polypeptide polymer atoms science scientific health molecular model 3d rendering illustration

Sclerostin (murine) Protein. Causes Decreased Bone Formation By Inhibiting The Wnt Signaling Pathway. Target Of Romosozumab, A Royalty-Free Stock Photo


Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a Stock Photo
Download
Designed by
Title
Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a #188427699
Description

Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a monoclonal antibody for the treatment of osteoporosis. 3D rendering based on protein data bank entry 2kd3. Cartoon representation with secondary structure coloring (green sheets, red helices

Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a
Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a
Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a
Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a
Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a

Sclerostin (murine) protein. Causes decreased bone formation by inhibiting the Wnt signaling pathway. Target of romosozumab, a
Murine sclerostin: target for osteoporosis treatment